Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) has announced upcoming presentation of preclinical data for OP-3136, their novel KAT6 inhibitor, at the 2025 AACR Annual Meeting in Chicago. The presentation will showcase the drug's anti-tumor activity in multiple solid tumor models, including prostate, ovarian, and non-small cell lung cancer.
The research demonstrates that OP-3136 functions as a potent and selective inhibitor of lysine acetyltransferase 6 (KAT6). Dr. Gopinath S. Palanisamy will present these findings in a late-breaking poster session (LB166) on April 28, 2025, from 9:00am-12:00pm CT.
Positive
- Demonstrated anti-tumor activity in multiple cancer types (prostate, ovarian, and lung cancer)
- Successfully developed a selective and potent KAT6 inhibitor
- Research selected for late-breaking presentation at major cancer conference
Negative
- Only preclinical stage data available
- No human clinical trial results yet
News Market Reaction
On the day this news was published, OLMA declined 1.19%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a poster highlighting preclinical anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell lung cancer models in a late-breaking session at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois.
Poster Presentation Details
Title: OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models
Poster/Abstract: LB166
Session: Late-Breaking Research: Tumor Biology 2
Date/Time: April 28, 2025, from 9:00am-12:00pm CT / 10:00am-1:00pm ET
Presenter: Dr. Gopinath S. Palanisamy, DVM, PhD
Additional information can be found on the AACR Annual Meeting website.
About OP-3136
OP-3136 is a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers. In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and synergistic with endocrine therapies, including palazestrant and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The Investigational New Drug (IND) application for OP-3136 was cleared by the U.S. Food and Drug Administration (FDA) in December 2024 and patients are currently enrolling in the Phase 1 clinical trial.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What is OP-3136 and how does it work against cancer?
Which cancer types showed response to OLMA's OP-3136 in preclinical studies?
When will Olema Oncology (OLMA) present the OP-3136 data at AACR 2025?
What type of presentation will OLMA deliver for OP-3136 at AACR 2025?
